Gossamer Bio Inc
Closed
SectorHealthcare
10.61 7,478.57
Overview
Share price change
24h
Min
0.11
Max
11.99
Income | 64M 17M |
|---|---|
Sales | -7.7M 9.2M |
EPS | -0.2 |
Profit margin | 182.94 |
Employees | 161 |
EBITDA | -28M -71M |
Next Earnings | 3 lis 2026 |
|---|
Market Cap | -391K 86M |
|---|---|
Previous open | -7467.96 |
Previous close | 10.61 |
News Sentiment
By Acuity
76%
24%
311 / 339 Ranking in Healthcare
Gossamer Bio Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Gossamer Bio Inc Forecast
Sentiment
By Acuity
311 / 339 Ranking in Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.